Novel targeted therapies for eosinophilic disorders

被引：85

作者：

Wechsler, Michael E. ^{[1
]}

Fulkerson, Patricia C. ^{[2
]}

Bochner, Bruce S. ^{[3
]}

Gauvreau, Gail M. ^{[4
]}

Gleich, Gerald J. ^{[5
]}

Henkel, Tim ^{[6
]}

Kolbeck, Roland ^{[7
]}

Mathur, Sameer K. ^{[8
]}

Ortega, Hector ^{[9
]}

Patel, Jatin ^{[10
]}

Prussin, Calman ^{[11
]}

Renzi, Paolo ^{[12
]}

Rothenberg, Marc E. ^{[2
]}

Roufosse, Florence ^{[13
,14
]}

Simon, Dagmar ^{[15
]}

Simon, Hans-Uwe ^{[16
]}

Wardlaw, Andrew ^{[17
]}

Weller, Peter F. ^{[18
]}

Klion, Amy D. ^{[19
]}

机构：

[1] Harvard Univ, Sch Med, Brigham & Womens Hosp, Boston, MA USA

[2] Cincinnati Childrens Hosp, Med Ctr, Dept Pediat, Div Allergy & Immunol, Baltimore, MD USA

[3] Johns Hopkins Univ, Sch Med, Dept Med, Div Clin Immunol & Allergy, Baltimore, MD 21205 USA

[4] McMaster Univ, Hamilton, ON L8S 4L8, Canada

[5] Univ Utah, Dept Dermatol & Med, Salt Lake City, UT USA

[6] Ceptaris Therapeut, Malvern, PA USA

[7] MedImmune Resp Inflammat & Autoimmun, Gaithersburg, MD USA

[8] Univ Wisconsin, Sch Med, Dept Med, Div Allergy Pulm & Crit Care, Madison, WI 53706 USA

[9] GlaxoSmithKline Res & Dev Ltd, Res Triangle Pk, NC USA

[10] GlaxoSmithKline Res & Dev Ltd, Uxbridge, Middx, England

[11] NIAID, Lab Allerg Dis, Bethesda, MD 20892 USA

[12] Univ Montreal, Notre Dame Hosp, Montreal, PQ H3C 3J7, Canada

[13] Univ Libre Bruxelles, Erasme Hosp, Dept Internal Med, Brussels, Belgium

[14] Univ Libre Bruxelles, Inst Med Immunol, Gosselies, Belgium

[15] Univ Hosp Bern, Dept Dermatol, Inselspital, Bern, Switzerland

[16] Univ Bern, Inst Pharmacol, CH-3012 Bern, Switzerland

[17] Univ Leicester, Inst Lung Hlth, Dept Infect Immun & Inflammat, Leicester LE1 7RH, Leics, England

[18] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Boston, MA USA

[19] NIAID, Parasit Dis Lab, NIH, Bethesda, MD 20892 USA

来源：

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY | 2012年 / 130卷 / 03期

基金：

美国国家卫生研究院;

关键词：

Hypereosinophilic syndromes; eosinophil-associated gastrointestinal disorders; eosinophilic esophagitis; Churg-Strauss syndrome; IL-5; mepolizumab; reslizumab; IDIOPATHIC HYPEREOSINOPHILIC SYNDROME; ANTI-IL-5 MEPOLIZUMAB THERAPY; CHURG-STRAUSS-SYNDROME; T-CELL POPULATION; AIRWAY INFLAMMATION; PERIPHERAL-BLOOD; ANTI-INTERLEUKIN-5; ANTIBODY; INHIBITORY RECEPTORS; ALEMTUZUMAB THERAPY; MONOCLONAL-ANTIBODY;

D O I：

10.1016/j.jaci.2012.07.027

中图分类号：

R392 [医学免疫学];

学科分类号：

100102 ;

摘要：

Hypereosinophilic syndromes (HESs) are a diverse group of conditions characterized by clinical manifestations attributable to eosinophilia and eosinophilic infiltration of tissues. HESs are chronic disorders with significant morbidity and mortality. Although the availability of targeted chemotherapeutic agents, including imatinib, has improved quality of life and survival in some patients with HESs, additional agents with increased efficacy and decreased toxicity are sorely needed. The purpose of this review is to provide an overview of eosinophil biology with an emphasis on potential targets of pharmacotherapy and to provide a summary of potential eosinophil-targeting agents, including those in development, in clinical trials, or approved for other disorders. (J Allergy Clin Immunol 2012;130:563-71.)

引用

页码：563 / 571

页数：9

共 50 条

[31] Novel targeted combinational therapies for melanoma
Suriano, Robert
Tuli, Neha Y.
Geliebter, Jan
Tiwari, Raj K.
Wallack, Marc
CANCER RESEARCH, 2015, 75
[32] Novel targeted therapies in adrenocortical carcinoma
Konda, Bhavana
Kirschner, Lawrence S.
CURRENT OPINION IN ENDOCRINOLOGY DIABETES AND OBESITY, 2016, 23 (03) : 233 - 241
[33] Treatment of Pediatric Eosinophilic Esophagitis: Traditional and Novel Therapies
Sharlin C.S.
Mukkada V.A.
Putnam P.E.
Bolton S.M.
Current Gastroenterology Reports, 2023, 25 (11) : 289 - 298
[34] THE TREATMENT OF SYSTEMIC MASTOCYTOSIS AND EOSINOPHILIC DISORDERS: FROM SUPPORTIVE TO TARGETED
Mannelli, F.
HAEMATOLOGICA, 2019, 104 : 209 - 212
[35] Targeted Osmotic Lysis: A Novel Approach to Targeted Cancer Therapies
Gould, Harry J., III
Paul, Dennis
BIOMEDICINES, 2022, 10 (04)
[36] Metabolic disorders associated with the use of targeted cancer therapies
Kotecki, Nuria
Penel, Nicolas
Awada, Ahmad
CURRENT OPINION IN ONCOLOGY, 2015, 27 (03) : 258 - 266
[37] Dendritic Cell–Targeted Therapies to Treat Neurological Disorders
Asim Hussain
Hamza Rafeeq
Nimra Munir
Zara Jabeen
Nadia Afsheen
Khalil ur Rehman
Muhammad Bilal
Hafiz M. N. Iqbal
Molecular Neurobiology, 2022, 59 : 603 - 619
[38] Emerging Targeted Therapies for Neuromyelitis Optica Spectrum Disorders
Cristina Valencia-Sanchez
Dean M. Wingerchuk
BioDrugs, 2021, 35 : 7 - 17
[39] Emerging Targeted Therapies for Neuromyelitis Optica Spectrum Disorders
Valencia-Sanchez, Cristina
Wingerchuk, Dean M.
BIODRUGS, 2021, 35 (01) : 7 - 17
[40] A Novel Therapeutic Target for the Treatment of Eosinophilic Disorders
Legrand, Fanny
Alpaugh, Alexandra
Falahati, Rustom
Makiya, Michelle
Klion, Amy D.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2015, 135 (02) : AB221 - AB221

← 1 2 3 4 5 →